73 million courses of SP+AQ shipped to countries in West Africa's Sahel region

In the Sahel and sub-Sahel regions of Africa, Seasonal Malaria Chemoprevention (SMC) with SP+AQ (sulfadoxine-pyrimethamine + amodiaquine) is a cost-effective solution that has been shown to prevent up to 75% of malaria episodes in clinical trial settings: high-quality SMC costs less than USD 1 per season, while inpatient care for a case of severe malaria is estimated to cost USD 12–75.1,2,3

Thanks to the ACCESS-SMC project led by the Malaria Consortium, 73 million courses of SP+AQ were shipped to 12 countries in 2016,4 enough to protect 18 million children during the malaria season; the product is manufactured by MMV's partner Guilin Pharmaceutical, currently the sole supplier of prequalified SP+AQ.

In 2016, Guilin Pharmaceutical’s SP+AQ product became the first taste-masked dispersible formulation validated by the Global Fund Expert Review Panel for purchase by international agencies. To ensure a sustainable supply of dispersible SP+AQ, MMV completed a partner selection process to identify a second manufacturer, S Kant Healthcare, India, and is supporting the company through WHO prequalification of its product.

Working closely with national authorities across the Sahel, MMV has developed a multi-country forecasting tool to improve stock management of SMC drugs, tracking key data by year, country, number of eligible children and drug volumes required. MMV is currently working to make the tool open-access for the entire malaria community and is adding a component that shows funding needs. In parallel, MMV is spearheading the collection of scientific and stakeholder input on the desired attributes of next-generation SMC drugs as alternatives to SP+AQ.

Updated July 2017


1. Cairns M et al. “Estimating the potential public health impact of seasonal malaria chemoprevention in African children.” Nat Commun. 3:881 (2012).

2. WHO/GMP Technical Expert Group On Preventive Chemotherapy, Geneva 4–6 May 2011. Report of the technical consultation on seasonal malaria chemoprevention.

3. Lubell Y et al. “Cost-effectiveness of parenteral artesunate for treating children with severe malaria in sub-Saharan Africa.” Bull World Health Organ. 89(7):504-12 (2011).

4. Burkina Faso, Cameroon, Chad, Gambia, Guinea, Ghana, Guinea Bissau, Mali, Niger, Nigeria, Togo, Senegal.